REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure
Hagens Berman Sobol Shapiro LLP issued an investor alert publicizing a pending securities fraud class action against Regeneron Pharmaceuticals tied to disclosures around its Phase 3 Fianlimab-plus-Libtayo trial in metastatic melanoma. The complaint alleges Regeneron made misleading statements about the trial's statistical assumptions and protocol change, which was revealed before the May 15, 2026 announcement that the study missed significance on progression-free survival; the firm cites an $11 billion market-cap wipeout. The class period runs Aug. 1, 2025 through May 15, 2026, with a Sept.
Key figures
- Trial phase
- Phase 3
- Class period
- Aug. 1, 2025 - May 15, 2026
- Market cap wipeout
- $11 billion
- Lead plaintiff deadline
- Sept. 14, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.